Athira pharma announces encouraging results from shape phase 2 clinical trial of fosgonimeton for the treatment of parkinson's disease dementia and dementia with lewy bodies

Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic hgf system as a potential therapeutic approach for neurodegenerative diseases

ATHA Ratings Summary

ATHA Quant Ranking